European Psychiatry - Volume 41 - April 2017

763 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S710–S771 S759
damage. Lithium ascorbate showed a protective effect like carno-
sine. Lithium carbonate revealed no detectable influence on
biomolecules in the conditions of our experiment.
Conclusion Lithium ascorbate has a protective effect on blood
plasma proteins and lipids under ethanol-induced oxidative dam-
age of biomolecules.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1092
Drug prescriptions associated with
long acting. Pharmaco-economic
aspects
A. Riolo , F. Babici , F. Tassi ∗
ASS 1 Triestina, Department of Mental Health, Trieste, Italy
∗ Corresponding author.
Introduction The polypharmacy is a very controversial subject; it
brings together problems of interaction between drugs, side effects,
and rationality of co-prescriptions, pharmaco-economic aspects.
The long acting is useful to solve adherence to treatment but they
are often prescribed in polytherapy.
Method The aim of this studies is to compare long-acting
haloperidol, fluphenazine, risperidone and paliperidone regard to
prescribing associations and pharmaco-economy. Also we want
to consider for each long-acting which and how many drugs are
associated and the implications in terms of pharmaco-economics.
We examined all prescriptions (126 patients) over a period of
12months in a mental health center, identifying which long acting
had the best pharmaco-economic profile.
Results Despite being the less prescribed and not being associ-
ated with other psychiatric drugs, paliperidone palmitate shows
the best pharmaco-economic profile.
Conclusions The costs of a drug are in relationship not only with
unit price but also with the question of safety in order to oppose
the overmedication.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1093
Rasagiline and venlafaxine: The
serotonin syndrome
A. Rodriguez Campos ∗, L. Rodríguez Andrés , G. Medina Ojeda ,
L. Gallardo Borge , E. Rybak Koite
Hospital Clinico Universitario de Valladolid, Psychiatry Department,
Valladolid, Spain
∗ Corresponding author.
Rasagiline is a highly potent irreversible monoamine oxidase
(MAO)-B inhibitor, antiparkinsonian drug that may be used with
caution in patients treated with antidepressant drugs because of
the possible appearance of severe adverse effects. It is presented
the case report of a woman treated with rasagiline and venlafaxine
that presents confusion and a serotonin syndrome. Pathogenesis,
physiopathology and treatment are discussed. Growing evidence
suggests that Parkinson disease and depression are linked. Antide-
pressant drugs and PD treatment should be used with caution
because of possible drug interaction.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1094
A rare instance of tardive dyskinesia
with SSRI use: A case study
D. Roy
The Prince Charles Hospital Metro North Health Services, Acute Care
Team, Department of Psychiatry, Chermside, Australia
Introduction Case presentation of a middle aged lady Mrs. C.K.,
who developed tardive dyskinesia (TD) after a trial of an SSRI.
Case report A 49-year-old Australian aboriginal lady, presented
with involuntarymovement of her face (bucco-linguomasticatory),
movements after a 3months trial of sertraline (maximum dose of
100mg daily) for her depressive illness. There was no history of
trials with anti-psychotics or any other medications, which may
have caused the oral dyskinesias. Routine examinations including
cognitive testing, EEG and MRI revealed no pathological findings.
Her sertraline was ceased and she was commenced on mirtaza-
pine 15mg at night, which was hiked to 30mg after 1 week and
continued on this dose over the next 3months. She exhibited good
improvement in her depressive symptoms and a significant attenu-
ation of her TD’s. Involuntarymovement scale rating: she was rated
on the abnormal involuntary movement scale (AIMS) and showed
gradual improvement in the severity of her orofacial dyskinetic
movement. Her scores were–initial presentation (scored 22/36);
at 4 weeks (9/36); 8 weeks (6/36) and at 16 weeks (4/36).
Discussion Although TD’s are seen in approximately 1 to 5%
of mental health patients treated with anti-psychotics (and
some other medications like Levodopa, Metochlorpromide, etc.),
research studies on SSRI’s causing TD’s are rare and few (Leo et al.,
1996; Gerber et al., 1998).
Conclusions To alert and educate clinicians about a relatively rare
adverse-effect of SSRI producing an involuntary movement disor-
der.
Disclosure of interest
The author has not supplied his/her declaration of competing inter-
est.
EV1095
Sexual dysfunction associated with
antidepressants and how to prevent it.
Is vortioxetine effective?
H. Saiz Garcia ∗, L. Montes Reula , A. Portilla Fernandez ,
V. Pereira Sanchez , N. Olmo Lopez , E. Mancha Heredero ,
A.S. Rosero Enriquez , M.E. Martinez Parre˜no
1 Complejo Hospitalario Navarra, Psychiatry, Pamplona, Spain
2 Clinica Universidad de Navarra, Psychiatry, Pamplona, Spain
3 CSM Salburua, Psychiatry, Vitoria, Spain
∗ Corresponding author.
Introduction One of the most common, and many times hidden,
secondary effects of antidepressants drugs use is sexual dysfunc-
tion (SD). It has been noted that as many as 20% of patients
will discontinue treatment with an SSRI, with one-third of these
patients doing so due to adverse reactions.
Methodology A review was conducted aiming to clarify the
pathogenesis of sexual dysfunction in depressed patients or taking
antidepressants and how to prevent and manage it. The literature
search was conducted in PubMed data reviewing articles dating
between 2015 and 2016.
Results (1) the sexual response cycle is negatively affected in
individuals suffering from major depressive disorder, even before
initiation of any psychotropic medication. The serotonergic system
plays a largely inhibitory role on sexual desire, orgasm, and ejacula-
tion with involvement of the hippocampus and amygdala. Tricyclic
antidepressants increase the level of prolactin and indirectly sup-
press the level of testosterone. (2) Bupropion and vortioxetine are
the only antidepressants that have level 1 evidence supporting that